MADRIGAL PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Increase (Decrease) in Accounts Receivable of $57.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $4.96M, a 72.17% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $52.88M, a 595.24% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $21.19M, a 9.28% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $34.05M, a 44.52% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $80.65M, a 49.85% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $53.82M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $57.84M 10-Q · filed 2026-07-30 | $79.03M derived: sum of 3 quarters · filed 2026-07-30 | $113.08M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $52.88M 10-Q · filed 2026-05-06 | $74.07M derived: sum of 2 quarters · filed 2026-05-06 | $108.13M derived: sum of 3 quarters · filed 2026-05-06 | $125.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $55.24M derived: sum of 2 quarters · filed 2026-02-19 | $73.05M derived: sum of 3 quarters · filed 2026-07-30 | $80.65M 10-K · filed 2026-02-19 |
| 2025-09-30 | $34.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $51.86M derived: sum of 2 quarters · filed 2026-07-30 | $59.46M 10-Q · filed 2025-11-04 | $82.82M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $17.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $25.41M 10-Q · filed 2026-07-30 | $48.77M derived: sum of 3 quarters · filed 2026-07-30 | $72.33M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $7.61M 10-Q · filed 2026-05-06 | $30.96M derived: sum of 2 quarters · filed 2026-05-06 | $54.53M derived: sum of 3 quarters · filed 2026-05-06 | $61.43M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $23.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $46.92M derived: sum of 2 quarters · filed 2026-02-19 | $53.82M derived: sum of 3 quarters · filed 2026-02-19 | $53.82M 10-K · filed 2026-02-19 |
| 2024-09-30 | $23.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $30.46M derived: sum of 2 quarters · filed 2025-11-04 | $30.46M 10-Q · filed 2025-11-04 | $30.46M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $6.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $6.90M 10-Q · filed 2025-08-05 | $6.90M derived: sum of 3 quarters · filed 2026-02-19 | $6.90M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2016-12-31 | -$7.33K 10-K · filed 2017-03-31 | |||
| 2015-12-31 | -$38.82K 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |